Morgan Stanley Initiates Coverage of Revolution Medicines with Overweight
Fintel reports that on September 10, 2026, Morgan Stanley initiated coverage of Revolution Medicines (NASDAQGS:RVMD) with a Overweight recommendation.
Prior to this rating action, the stock closed at $207.68 on September 9, 2026. Looking at recent market performance, the company's share price experienced a price change of -0.74% over one week, relative to a baseline close of $209.23 on September 2, 2026. Over a one-month period, the price change was +1.23% from a baseline close of $205.15 on August 7, 2026. The latest close recorded on September 9, 2026, was also $207.68.
Separately from Morgan Stanley's individual rating, aggregate analyst data shows a current consensus target mean of $249.81 and a median of $244.80 as of August 28, 2026. This mean target represents an implied change of +20.29% from previous levels. The prior consensus target mean was $211.24 as of August 4, 2026, reflecting a consensus target revision of +18.26%. In terms of overall analyst recommendations, the current recommendation period as of September 1, 2026, shows a total of 28 recommendations, consisting of 10 strong buy, 16 buy, 2 hold, 0 sell, and 0 strong sell ratings. This breakdown represents 92.9% positive, 7.1% hold, and 0.0% negative recommendations, which remains unchanged from the prior recommendation period as of August 1, 2026, which also had 28 total recommendations with the same distribution.
Other analyst firms have also recently updated their views on the biotechnology company. On September 9, 2026, Stifel maintained its Buy rating. Prior to that, Needham maintained its Buy rating on August 31, 2026, while UBS and Guggenheim both maintained their Buy ratings on August 28, 2026. Additionally, HC Wainwright & Co. maintained its Buy rating and Evercore ISI Group maintained its Outperform rating on August 27, 2026. In its latest earnings report on August 5, 2026, Revolution Medicines reported an actual EPS of -3.06, compared to an estimated EPS of -2.0173. The actual revenue was reported as $0.00, against an estimated revenue of $16,702,204,000,000.00.
According to its Form 10-Q quarterly report filed with the United States Securities and Exchange Commission on August 5, 2026, for the quarterly period ended June 30, 2026, Revolution Medicines, Inc. is a Delaware corporation with principal executive offices located at 700 Saginaw Drive, Redwood City, CA 94063. The company operates in the biotechnology industry, focusing on developing novel therapies to inhibit frontier cancer targets within notorious cancer pathways. Its platform is designed to generate small molecules tailored to counter elusive, high-value RAS(ON) and mTOR pathway targets, with key projects aimed at advancing a diverse pipeline of drugs for multi-faceted anti-tumor activities.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 10, 2026 | Morgan Stanley | Overweight | initiated coverage | |
| September 9, 2026 | Stifel | Buy | Buy | maintained |
| August 31, 2026 | Needham | Buy | Buy | maintained |
| August 28, 2026 | UBS | Buy | Buy | maintained |
| August 28, 2026 | Guggenheim | Buy | Buy | maintained |
| August 27, 2026 | HC Wainwright & Co. | Buy | Buy | maintained |
| August 27, 2026 | Evercore ISI Group | Outperform | Outperform | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.